NCS-01 for Stroke
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new treatment called NCS-01 to see if it is safe for patients who have recently had a stroke. The study will check how well patients tolerate the treatment.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is NCS-01 safe for use in humans?
How is the NCS-01 treatment different from other stroke treatments?
NCS-01 is a novel cell-based therapy using bone marrow-derived cells that show promise in improving motor and neurological function after a stroke. Unlike traditional treatments, NCS-01 cells secrete therapeutic factors and extend filopodia (tiny projections) towards the injury site, potentially offering a unique mechanism for recovery.12678
What data supports the effectiveness of the drug NCS-01 for stroke?
Who Is on the Research Team?
Sean Savitz
Principal Investigator
The University of Texas Health Science Center, Houston
Are You a Good Fit for This Trial?
This trial is for men and women aged 18-85 who've had a recent stroke with certain levels of neurological deficits. They must be able to undergo an MRI, not have cancer in the last 5 years, no organ transplants, not in another drug study recently, and women must use birth control.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Randomization and Initial Treatment
Participants are randomized within 48 hours of stroke onset and receive either the sham procedure or NCS-01 treatment
Treatment and Monitoring
Participants undergo treatment and are monitored for changes in NIHSS, ECG, and adverse events
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- NCS-01
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
NC Medial Research Inc
Lead Sponsor